IMMUNITYBIO, INC. Debt and Equity Securities, Unrealized Gain (Loss)
IMMUNITYBIO, INC. (IBRX) reported Debt and Equity Securities, Unrealized Gain (Loss) of $1.59 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss · last filed 2026-05-07
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.59M, a 155.39% increase year-over-year.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $4.00K.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for the quarter ending 2025-06-30 was -$3.00K.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for fiscal 2025 was $0.00.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for fiscal 2024 was -$632.00K.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for fiscal 2023 was -$1.59M.
- IMMUNITYBIO, INC. debt and equity securities, unrealized gain (loss) for fiscal 2022 was -$4.19M.
| Period end | Debt and Equity Securities, Unrealized Gain (Loss) 3 month | Debt and Equity Securities, Unrealized Gain (Loss) 3 month as first filed | Debt and Equity Securities, Unrealized Gain (Loss) 6 month | Debt and Equity Securities, Unrealized Gain (Loss) 9 month | Debt and Equity Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $1.59M 10-Q · filed 2026-05-07 | $1.59M derived: sum of 2 quarters · filed 2026-05-07 | $1.59M derived: sum of 3 quarters · filed 2026-05-07 | $1.59M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.00K derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2025-09-30 | $4.00K 10-Q · filed 2025-11-05 | $1.00K derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $510.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-06-30 | -$3.00K 10-Q · filed 2025-08-05 | -$4.00K 10-Q · filed 2025-08-05 | $506.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-03-31 | $621.00K 10-Q · filed 2026-05-07 | -$1.00K 10-Q · filed 2025-05-12 | $509.00K derived: sum of 2 quarters · filed 2026-05-07 | $4.00K derived: sum of 3 quarters · filed 2026-05-07 | -$736.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$617.00K derived: sum of 2 quarters · filed 2026-02-23 | -$1.36M derived: sum of 3 quarters · filed 2026-02-23 | -$632.00K 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$505.00K 10-Q · filed 2025-11-05 | -$1.25M derived: sum of 2 quarters · filed 2025-11-05 | -$520.00K 10-Q · filed 2025-11-05 | -$1.26M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | -$740.00K 10-Q · filed 2025-08-05 | -$15.00K 10-Q · filed 2025-08-05 | -$755.00K derived: sum of 3 quarters · filed 2026-02-23 | -$1.35M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $725.00K 10-Q · filed 2025-05-12 | -$15.00K derived: sum of 2 quarters · filed 2026-02-23 | -$608.00K derived: sum of 3 quarters · filed 2026-02-23 | -$1.00M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.33M derived: sum of 2 quarters · filed 2026-02-23 | -$1.73M derived: sum of 3 quarters · filed 2026-02-23 | -$1.59M 10-K · filed 2026-02-23 | |
| 2023-09-30 | -$593.00K 10-Q · filed 2024-11-12 | -$986.00K derived: sum of 2 quarters · filed 2024-11-12 | -$851.00K 10-Q · filed 2024-11-12 | -$5.20M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$393.00K 10-Q · filed 2024-08-12 | -$258.00K 10-Q · filed 2024-08-12 | -$4.61M derived: sum of 3 quarters · filed 2025-03-03 | -$4.00M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $135.00K 10-Q · filed 2024-05-09 | -$4.22M derived: sum of 2 quarters · filed 2025-03-03 | -$3.60M derived: sum of 3 quarters · filed 2025-03-03 | -$5.47M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$3.74M derived: sum of 2 quarters · filed 2025-03-03 | -$5.61M derived: sum of 3 quarters · filed 2025-03-03 | -$4.19M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $614.00K 10-Q · filed 2023-11-09 | -$1.26M derived: sum of 2 quarters · filed 2023-11-09 | $162.00K 10-Q · filed 2023-11-09 | -$6.84M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | -$1.87M 10-Q · filed 2023-08-08 | -$452.00K 10-Q · filed 2023-08-08 | -$7.45M derived: sum of 3 quarters · filed 2024-03-19 | -$13.46M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $1.42M 10-Q · filed 2023-05-11 | -$5.58M derived: sum of 2 quarters · filed 2024-03-19 | -$11.59M derived: sum of 3 quarters · filed 2024-03-19 | -$12.03M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$13.01M derived: sum of 2 quarters · filed 2024-03-19 | -$13.45M derived: sum of 3 quarters · filed 2024-03-19 | -$4.62M 10-K · filed 2024-03-19 | |
| 2021-09-30 | -$6.01M 10-Q · filed 2022-11-09 | -$6.45M derived: sum of 2 quarters · filed 2022-11-09 | $2.38M 10-Q · filed 2022-11-09 | $3.47M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$442.00K 10-Q · filed 2022-08-08 | $8.39M 10-Q · filed 2022-08-08 | $9.48M derived: sum of 3 quarters · filed 2023-03-01 | $9.47M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $8.83M 10-Q · filed 2022-05-10 | $9.92M derived: sum of 2 quarters · filed 2023-03-01 | $9.92M derived: sum of 3 quarters · filed 2023-03-01 | $10.61M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.08M derived: sum of 2 quarters · filed 2023-03-01 | $1.77M derived: sum of 3 quarters · filed 2023-03-01 | $1.58M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$4.00K 10-Q · filed 2021-11-12 | $688.00K derived: sum of 2 quarters · filed 2021-11-12 | $490.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $692.00K 10-Q · filed 2021-08-12 | $494.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$198.00K 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | -$321.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |